ESC 365 - Balancing residual inflammatory, lipid, and thrombotic risk in coronary artery disease

ESC Premium Access

Balancing residual inflammatory, lipid, and thrombotic risk in coronary artery disease

Session: Innovative strategies for secondary prevention

Topic: Treatment

Speaker: Professor P. Libby (Boston, US)

Event: ESC Congress 2018

Congress Presentation

About the speaker

Professor Peter Libby

Brigham and Women's Hospital, Boston (United States of America)

31 presentations

5 followers

3 more presentations in this session

Innovative strategies for lipid lowering treatment: PCSK9 inhibition

Speaker: Professor F. Mach (Geneva, CH)

Anti-inflammatory therapy : interleukin-1 beta inhibition to prevent cardiovascular events

Speaker: Doctor P. Ridker (Boston, US)

Prolonged P2Y12 inhibition or Factor Xa inhibition in patients after an acute coronary syndrome

Speaker: Doctor T. Cuisset (Marseille, FR)

Access the full session

Innovative strategies for secondary prevention

Speakers: Professor P. Libby, Professor F. Mach, Doctor P. Ridker, Doctor T. Cuisset

About the event

ESC Congress 2018

7 November - 29 August 2018

Sessions Presentations

Congress

Related content

Open Access

SGLT-2 Inhibitors in Heart Failure: Where are we now and where are we heading?

27 August 2021

Open Access

GUIDE-HF - Panel discussion.

27 August 2021

Open Access

Panel Discussion: The case for combination therapy: The way forward in intensive LDL-c management?

27 August 2021

ESC 365 is supported by